Current strategies using CRISPR system can be divided into two categories: 1) reactivate the γ-globin gene expression to compensate the defective β-globin level and 2) direct restoration of genetic mutations in HBB genes particular for treating SCD. This evidence concerns the gene HBB and Schnyder corneal dystrophy.